BB, AMRN has suggested it will consider BOTH legal and administrative
remedies to the generic issues. What is your answer/opinions on the
following:
1. Could the FDA rescind the Marine indication for Vascepa?
2. What (other) administrative action(s) could the FDA take?
3. Any ideas on how the generic Lovaza problem could be solved?
What bothers me is that AMRN has never figured out a way to prevent
generic Lovaza from eating AMRN's lunch.
Why won't the FDA step up and provide some means to insure that Vascepa
and Vascepa alone is available for CVD patients? All this other crap,
including fish oil supplements is hurting CV patients if they are taking
something that does not work and is potentially harmful, when their
exists something PROVEN to benefit CVD patients. 4. Would the FDA be more
"helpful" if a BP like Pfizer owned AMRN?
News 
Market Data 
Discover 
AI
